TITLE

FDA Actions

AUTHOR(S)
Elliott, William T.
PUB. DATE
July 2009
SOURCE
Travel Medicine Advisor;Jul2009 Pharmacology Watch, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on U.S. Food and Drug Authority (FDA) advisories as of July 2009 on certain drugs. FDA has approved AndroGel 1% and Testim 1% which claimed topical testosterone stamina pending the inclusion of a label warning against secondary exposure on children. Likewise, FDA has approved the use of Iloperidone, an atypical antipsychotic drug, so long as it carries a boxed warning. Hydroxycut dietary supplements claiming weight loss were pulled out from market due to reported serious health consequences of users.
ACCESSION #
41994519

 

Related Articles

  • Thinking of Taking Supplements?  // Diabetes Health;Oct2004, Vol. 13 Issue 10, p34 

    Presents several factors to be considered before taking a dietary supplement for diabetes. Absence of drug approval by the U.S. Food and Drug Administration (FDA); Responsibilities of manufacturers regarding the use of dietary supplements; Information required by the FDA to appear on dietary...

  • FDA targets miracle weight loss claims. Devaney, Tim // Hill;11/4/2014, Vol. 21 Issue 110, p17 

    The article reports that the U.S. Food and Drug Administration (FDA) issues new guidelines for the manufacturers of dietary supplements, in an effort to tamp down on misleading weight loss claims.

  • Magic bullet for weight management? Elliott, William T. // OB/GYN Clinical Alert;Aug2012 Pharmacology Watch, p1 

    The article informs that lorcaserin, the first medicine for weight loss has been approved by the U.S. Food and drug Association (FDA).

  • Qsymia OK'd for Obesity.  // Monthly Prescribing Reference;Aug2012, Vol. 28 Issue 8, pA-15 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of Vivus Pharmaceuticals' Qsymia, a drug which is indicated as an adjunct to a reduced-calorie diet for chronic weight management.

  • Weight loss category gains competitor in Qsymia. Weinstein, Deborah // Medical Marketing & Media;Aug2012, Vol. 47 Issue 8, p10 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of two weight loss drugs, Belviq from Arena Pharmaceuticals Inc. and Qsymia from Vivus Inc.

  • FDA Approves First New Anti-Obesity Drug in Years. Elliott, William T. // Internal Medicine Alert;7/15/2012 Supplement, p1 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved the anti-obesity drug Lorcaserin.

  • FDA denies approval of weight-loss drug.  // Endocrine Today;Feb2011, Vol. 9 Issue 2, p4 

    The article reports on a response letter sent by the U.S. Food and Drug Administration (FDA) in which they claimed that a new drug application for combination naltrexone plus bupropion extended-release tablets for obesity treatment was not approved.

  • Drugs in the News.  // Clarendon Enterprise (TX);7/11/2013, Vol. 24 Issue 28, p10 

    The article reports on the approval of the weight reducing drug Belviq (lorcaserin) by the Food and Drug Administration (FDA) in June 2012 as well as its release in the U.S. market.

  • Belviq OK'd for Weight Loss.  // Monthly Prescribing Reference;Aug2012, Vol. 28 Issue 8, pA-15 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of Eisai Co. Ltd.'s Belviq, a drug which is indicated as an adjunct to a reduced-calorie diet for chronic weight management.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics